Pacira Pharmaceuticals, Inc. Form 3 May 04, 2016 FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

**OMB APPROVAL** 

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

\_ Form filed by More than One

Person

\_\_\_\_

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Reinhart Charles A. III	<ul><li>2. Date of Event Requiring</li><li>Statement</li><li>(Month/Day/Year)</li></ul>	3. Issuer Name <b>and</b> Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]			
(Last) (First) (Middle)	05/03/2016	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O PACIRA PHARMACEUTICALS,		(Check all applicable)	``````````````````````````````````````		
INC., 5 SYLVAN WAY, SUITE 300		Director 10% Owner X_ Officer Other			
(Street)		(give title below) (specify below) Chief Financial Officer	6. Individual or Joint/Group		

Chief Financial Officer

## PARSIPPANY, NJÂ 07054

R 0

					Reporting Person
(City)	(State)	(Zip)	Table I - Non-Deriv	ative Securit	ies Beneficially Owned
.Title of Secu Instr. 4)	ırity		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
	port on a sepa		ass of securities beneficially	SEC 1473 (7-02	2)
		•	d to the collection of d in this form are not		

required to respond unless the form displays a

currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

### Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 3

Date	Expiration	Title	Amount or	Security	Direct (D)
Exercisable	Date		Number of		or Indirect
			Shares		(I)
					(Instr. 5)

# **Reporting Owners**

Reporting Owner Name / Address		Relationships					
· · · · · · · · · · · · · · · · · · ·	Direc	tor 1	0% Owner	Officer	Other		
Reinhart Charles A. III C/O PACIRA PHARMACEUTICALS, IN 5 SYLVAN WAY, SUITE 300 PARSIPPANY, NJ 07054	NC.	Â	Â	Chief Financial Officer	Â		
Signatures							
/s/ Kristen Williams, Attorney-in-Fact	05/04/2016						
**Signature of Reporting Person	Date						
Explanation of Responses:							

# **EXPLANATION OF RESPONSES:** No securities are beneficially owned

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.